TGF?s and other structurally related proteins of the TGF? superfamily, such as BMPs, GDFs, and activins, are secreted signaling proteins that regulate many essential processes, ranging from establishment of the body plan during embryogenesis to regulation of the adaptive immune system. The importance of the more than 30 superfamily members is demonstrated by the many human diseases that result from dysregulation of the pathway, including skeletal and cardiac disorders, infertility, and cancer. The development of effective therapies for treating pathway-associated diseases requires knowledge of the interactions that govern ligand activities - this includes interactions with the signaling receptors, but as well with the many accessory proteins that bind ligands and regulate ligand accessibility. The objective of this project is to capitalize upon our current understanding of how TGF?s bind their signaling receptors to investigate how betaglycan, a membrane- anchored accessory binding proteolgycan, functions on the one hand to promote TGF? signaling, and on the other to inhibit activin signaling. The potentiation of TGF? signaling by betaglycan is thought to arise from its ability to bind and localize TGF? ligands on the cell surface. To investigate this, we will determine the structures of betaglycan's two independent TGF? binding domains, BGE and BGU, bound to TGF? using crystallography, which is ideal for these purposes, as BGE and BGU bind and form highly stable complexes with TGF?. The mechanisms for potentiation of receptor binding suggested by the structure of the complexes will be tested in functional assays. The inhibition of activin signaling by betaglycan is thought to be mediated by sequestration of the activin type II receptor, ActRII or the close homolog ActRIIb, in a ternary complex with betaglycan and inhibin A, a heterodimeric ligand with an activin ? subunit that binds the activin type II receptor, ActRII/ActRIIb, and an activin ? subunit that binds BGU, betaglycan's C-terminal binding domain. To investigate this, we will first determine how activins bind their type I receptor, ActRIb. These studies will be carried out using NMR as ActRIb binds activin A weakly. This will be further investigated by determining the structure of inhibin A bound to BGU using crystallography, which is ideal for these purposes as BGU binds and forms a highly stable complex with inhibin A. The mechanisms for antagonism of activin by inhibin A suggested by the structure of the complexes will be tested in functional assays. The feasibility of the proposed studies is demonstrated by diffracting crystals obtained for the BGE:T?RII:TGF? complex, the ability to isolate the BGUC:TGF? complex, and NMR signal assignments for ActRIb. The determination of these structures will provide an important missing link in our understanding of how one of the accessory proteins of the superfamily, betaglycan, influences downstream signaling induced by TGF?s and activin. The structures will also aid in the development of novel targeted-therapies for treatment of diseases and disorders, such as cancer and infertility, caused by aberrant TGF? and activin signaling.

National Institute of Health (NIH)
Research Project (R01)
Project #
Application #
Study Section
Macromolecular Structure and Function B Study Section (MSFB)
Program Officer
Smith, Ward
Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
Total Cost
Indirect Cost
University of Texas Health Science Center
Schools of Medicine
San Antonio
United States
Zip Code
Huang, Tao; Schor, Seth L; Hinck, Andrew P (2014) Biological activity differences between TGF-?1 and TGF-?3 correlate with differences in the rigidity and arrangement of their component monomers. Biochemistry 53:5737-49
Huang, Tao; David, Laurent; Mendoza, Valentín et al. (2011) TGF-? signalling is mediated by two autonomously functioning T?RI:T?RII pairs. EMBO J 30:1263-76
Zuniga, Jorge E; Ilangovan, Udayar; Mahlawat, Pardeep et al. (2011) The T*R-I pre-helix extension is structurally ordered in the unbound form and its flanking prolines are essential for binding. J Mol Biol 412:601-18
Li, Lingyin; Orner, Brendan P; Huang, Tao et al. (2010) Peptide ligands that use a novel binding site to target both TGF-* receptors. Mol Biosyst 6:2392-402
Radaev, Sergei; Zou, Zhongcheng; Huang, Tao et al. (2010) Ternary complex of transforming growth factor-beta1 reveals isoform-specific ligand recognition and receptor recruitment in the superfamily. J Biol Chem 285:14806-14
Garza, John A; Ilangovan, Udayar; Hinck, Andrew P et al. (2009) Kinetic, dynamic, ligand binding properties, and structural models of a dual-substrate specific nudix hydrolase from Schizosaccharomyces pombe. Biochemistry 48:6224-39
Mendoza, Valentin; Vilchis-Landeros, M Magdalena; Mendoza-Hernandez, Guillermo et al. (2009) Betaglycan has two independent domains required for high affinity TGF-beta binding: proteolytic cleavage separates the domains and inactivates the neutralizing activity of the soluble receptor. Biochemistry 48:11755-65
Baardsnes, Jason; Hinck, Cynthia S; Hinck, Andrew P et al. (2009) TbetaR-II discriminates the high- and low-affinity TGF-beta isoforms via two hydrogen-bonded ion pairs. Biochemistry 48:2146-55
Xu, Xiaoping; Mikhailova, Margarita; Ilangovan, Udayar et al. (2009) Nuclear magnetic resonance mapping and functional confirmation of the collagen binding sites of matrix metalloproteinase-2. Biochemistry 48:5822-31
Ilangovan, Udayar; Bhuiyan, Shakhawat H; Hinck, Cynthia S et al. (2008) A. fulgidus SRP54 M-domain. J Biomol NMR 41:241-8

Showing the most recent 10 out of 18 publications